Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance

Daré Bioscience received a deficiency notice from Nasdaq regarding its minimum bid price, indicating that its stock price has fallen below the required threshold. The company has until March 29, 2027, to regain compliance with Nasdaq's listing requirements. This notice highlights potential challenges for Daré Bioscience in maintaining its stock market listing.